|Ayumu Ito1, Shigehisa Kitano2,3*, Yongji Kim4, Moeko Inoue3, Masanori Fuse3, Kohei Tada3, and Kiyoshi Yoshimura2,3|
|1Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan|
|2Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan|
|3Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan|
|4Department of Orthopedic Surgery, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan|
|Corresponding Author :||Shigehisa Kitano
National Cancer Center5-1-1 Tsukiji
Chuo-ku, Tokyo 104-0045, Japan
Email: [email protected]
|Received: March 05, 2015; Accepted: April 23, 2015; Published: April 28, 2015|
|Citation: Ito A, Kitano S, Kim Y, Inoue M, Fuse M, et al. (2015) Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy. J Clin Cell Immunol 6:322. doi:10.4172/2155-9899.1000322|
|Copyright: ©2015 Ito A et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Visit for more related articles at Journal of Clinical & Cellular Immunology
Recent progress in cancer immunotherapy has been remarkable, especially the clinical development of immune checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1 antibodies. The success of these agents has revealed the importance of anti-tumor immune activities in curing cancers.
Cancer peptide vaccines constitute another approach to eliciting and boosting anti-tumor immune responses. While conventional cancer vaccines have had limited clinical efficacy, targeting mainly tumor-associated selfantigens, a novel approach is now being explored to target tumor-specific antigens generated from gene mutations occurring in tumor cells during neoplastic transformation. Theoretically, immune responses to these so-called “cancer neoantigens” are not attenuated by host central tolerance in the thymus and do not trigger autoimmune reactions. Despite these theoretical considerations, until recently there were major technical difficulties in applying neoantigen-based cancer vaccines to bedside practice, because the mutations in each tumor are so numerous and which one/subset of neoantigens would be immunogenic enough to eliminate the tumor is uncertain. Recent developments in genomics and bioinformatics, including massively parallel sequencing (MPS) and epitope prediction algorithms, have provided a major breakthrough, enabling more comprehensive and efficient identification of target antigens. Although further refinements are needed for actual bedside application, the preclinical and clinical evidence for the effectiveness of targeting cancer neoantigens continues to accumulate.
In this review, we discuss the current status and future challenges of developing neoantigen-based personalized immunotherapy.